ENDO: Teprotumumab Shows Long-Term Efficacy for Thyroid Eye Disease
Inflammatory and ophthalmic composite outcome improvements seen in 90 percent of patients at 72 weeks
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.